
ESMO data show the phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab improved recurrence-free survival in resected stage IIB to IV melanoma.
Management of a Patient With a Very Large Ocular CSCC Tumor
A 64-Year-Old Woman With Very Large Ocular CSCC Tumor